New NNT→Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. https://t.co/gr2UgM6ST3
RT @rauldsf_santos: Also SAFEHEART risk equation helps identify higher risk FH individuals! https://t.co/v7e9vMJ9Ai https://t.co/CI0N5jlkd2…
RT @rauldsf_santos: Also SAFEHEART risk equation helps identify higher risk FH individuals! https://t.co/v7e9vMJ9Ai https://t.co/CI0N5jlkd2…
Also SAFEHEART risk equation helps identify higher risk FH individuals! https://t.co/v7e9vMJ9Ai https://t.co/CI0N5jlkd2 @HFIberoamerica @FHFamiliar
RT @rauldsf_santos: Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults wit…
RT @rauldsf_santos: Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults wit…
RT @atherosociety: Decision tools are needed to increase cost effectiveness of PCSK9 inhibitors in FH! https://t.co/yQlbRvG7C0
RT @atherosociety: Decision tools are needed to increase cost effectiveness of PCSK9 inhibitors in FH! https://t.co/yQlbRvG7C0
RT @atherosociety: Decision tools are needed to increase cost effectiveness of PCSK9 inhibitors in FH! https://t.co/yQlbRvG7C0
RT @rauldsf_santos: Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults wit…
RT @atherosociety: Decision tools are needed to increase cost effectiveness of PCSK9 inhibitors in FH! https://t.co/yQlbRvG7C0
RT @rauldsf_santos: Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults wit…
Decision tools are needed to increase cost effectiveness of PCSK9 inhibitors in FH!
Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia https://t.co/4XBBO1BxTr @HFIberoamerica @atherosociety
RT @EASCongress: Published in the current issue of our journal https://t.co/gNtrE1t8ic
Published in the current issue of our journal
Published in the July issue of our journal
Journal highlights July
Congratulations @rauldsf_santos and @ProfKausikRay with this valuable article! Enjoyed reading it!
RT @rauldsf_santos: Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults wit…
RT @rauldsf_santos: Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults wit…
RT @rauldsf_santos: Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults wit…
Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. Risk stratification in FH, moving forward ! https://t.co/WBB2npb1kl